Dexamethasone treatment in patients with brain metastases and primary brain tumors: do the benefits outweigh the side-effects?

Abstract

In order to minimize neurological symptoms and treatment-related side-effects, patients with primary or secondary brain tumors receive dexamethasone. The goal of this study was to analyze dosage and duration of dexamethasone intake and to compare the advantages and disadvantages of this medication during the course of radiation therapy (RT). Data from 138 consecutive patients were therefore analyzed retrospectively. During the course of therapy, the dosage of dexamethasone was evaluated, as were the indications for and duration of this treatment, its side-effects and any clinical changes reported during dexamethasone intake. The dosage of dexamethasone was higher at the outset and during RT (median 7-12 mg/day) than at the end of RT (median 1-6 mg/day). The average duration of dexamethasone intake was 23 weeks for patients with primary, and 7 weeks for patients with secondary brain tumors. The most frequent side-effects were a rise in serum glucose level, peripheral edema, psychiatric disorders, and Cushing's syndrome. Life-threatening complications remained rare. Initially, dexamethasone led to good clinical improvement with few side-effects of RT, whereas by the end of RT the symptom relief was slight and toxicity increased. In a group of 13 patients who received no dexamethasone during RT, 12 showed neither RT-related side-effects nor of neurological impairment. Dexamethasone effectively minimizes neurological symptoms and RT-related side-effects in patients with primary and secondary brain tumors. Nevertheless, the side-effects of dexamethasone itself increase over time. For this reason, a generalized dose scheme should not be used. Instead, dosage should be adapted to each patient's individual needs. Future prospective studies will have to determine whether dexamethasone is advantageous on balance or not.

Effects of Dexamethasone and Placebo on Symptom Clusters in Advanced Cancer Patients: A Preliminary Report

“…It is important to remember, however, that dose and time are important factors in treating patients with advanced cancer. The administration of high doses of dexamethasone over a long period may not be practical because of the high frequency of adverse effects [56]. Furthermore, follow-up data for patients with advanced cancer are limited because of disease progression, and logistic issues are frequent problems in this cohort.…”

Use of Dexamethasone in Patients with High-Grade Glioma: A Clinical Practice Guideline

“…Dexamethasone was the most commonly used steroid, and doses in four studies ranged from 8 mg to 16 mg daily; one study reported the use of prednisone at 40 mg daily 7 . In a study reporting the results of two consecutive randomized trials involving 96 patients with brain metastases, Vecht et al 3 Retrospective studies and reviews report that the most common starting dose of dexamethasone ranges between 8 mg and 16 mg daily 5,6,8,12 . In a recent review of the role of steroids in the management of brain metastases, Ryken and colleagues concluded that symptomatic patients should be treated with a starting dose of 4-8 mg daily; if the patient exhibits severe symptoms associated with increased intracranial pressure, a dose of 16 mg daily or higher could be considered 9 .…”

“…Hyperglycemia has been reported in up to 72% of patients with primary brain tumours receiving dexamethasone 6 and might be associated with shorter survival in those patients 39,40 . The hyperglycemia from corticosteroid therapy usually occurs in the first 6 weeks of therapy and is believed to be secondary to insulin resistance and increased hepatic gluconeogenesis 24 .…”

ACR Appropriateness Criteria® Pre-Irradiation Evaluation and Management of Brain Metastases

“…Hempen et al 31 studied 138 patients with primary or metastatic brain tumors treated with radiation therapy. Ninety-one patients with brain metastases were treated with standard-fraction whole-brain radiation therapy for 2-3 ACR APPROPRIATENESS CRITERIA â weeks.…”